HIV Market Focus Theratechnologies is a commercial-stage biopharma currently marketing HIV prescription products in the United States, indicating an established access point to HIV care networks and payer discussions that can be leveraged for expanding HIV therapies or related metabolic health programs.

EVAF & Cardiometabolic Recent ACTHIV 2025 data highlights the management of Excess Visceral Abdominal Fat in People with HIV, suggesting a niche area for expanded product education, physician outreach, and potential combination strategies with lipid and cardiometabolic risk management.

Oncology & Rare Pipeline focus on oncology and rare/niche populations presents opportunities to partner on targeted clinical development, accelerate access programs, or co-commercialization with specialty channels serving underserved patient groups.

Partnership Potential Existing licensing activity with Ionis Pharmaceuticals and a strong financing backbone support potential strategic alliances for RNA-targeted or novel modality therapies, enabling co-development, regional commercialization, or market expansion in Canada and beyond.

Data-Driven Selling Adopt and leverage BI and analytics tools (Power BI, Tableau, New Relic) to drive territory planning, outcome-focused messaging, and payer negotiations using real-world data from HIV care, EVAF, and cardio-oncology signals to optimize sales conversations.